Sionna Therapeutics, Inc. - 8-K Filing

Sionna Therapeutics reports Q3 2026 net loss of $32.4 million and announces workforce reduction of approximately 46%. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $SION

Read the full article at SEC EDGAR

More Regulatory news